SCHEMBL214901

SCHEMBL214901

C[C@H](O)c1cccc(C#N)c1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.46
GLA P06280 1/20 0.44
GSK3B P49841 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ADRA1D P25100 4/20 0.43
ADRA1A P35348 2/20 0.43
ADRA2B P18089 1/20 0.43
S1PR1 P21453 2/20 0.43
GRM4 Q14833 1/20 0.43
UGT2B7 P16662 1/20 0.42
ADRA1B P35368 1/20 0.42
GPR139 Q6DWJ6 1/20 0.42
TNF P01375 1/20 0.40
CNR1 P21554 4/20 0.40
CNR2 P34972 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4095529 1.00 ENPP2 (0.46) ENPP2GLAGSK3BMEN1KMT2A
SCHEMBL30583447 1.00 ENPP2 (0.46) ENPP2GLAGSK3BMEN1KMT2A
SCHEMBL320196 1.00 ENPP2 (0.46) ENPP2GLAGSK3BMEN1KMT2A
SCHEMBL29857813 1.00 ENPP2 (0.46) ENPP2GLAGSK3BMEN1KMT2A
SCHEMBL1022809 0.86 ENPP2 (0.44) ENPP2GLAGSK3BADRA1DADRA1A
SCHEMBL11601220 0.83 ENPP2 (0.48) ENPP2GSK3BMEN1KMT2AADRA1D
SCHEMBL4693798 0.83 ENPP2 (0.48) ENPP2GSK3BMEN1KMT2AADRA1D
SCHEMBL104898 0.83 GLA (0.46) ENPP2GLAGSK3BADRA1DADRA1A
SCHEMBL27475654 0.82 GSK3B (0.46) ENPP2GLAGSK3BADRA1DADRA1A
SCHEMBL15617615 0.82 ESR1 (0.44) ENPP2GLAGSK3BADRA1DADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174683-A1 MAP4K1 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2024-05-30 US disclosed
EP-4288437-A1 MAP4K1 INHIBITORS Bayer Aktiengesellschaft (DE) 2023-12-13 EP disclosed
EP-3912620-A1 METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS PACIFIC NORTHWEST RESEARCH INSTITUTE (US) 2021-11-24 EP disclosed
CN-109689661-B Macrocyclic inhibitors of myeloperoxidase 百时美施贵宝公司 2021-10-15 CN disclosed
EP-3204120-B1 METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS PACIFIC NORTHWEST RES INSTITUTE (US) 2021-05-26 EP disclosed
US-20200338036-A1 METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS PACIFIC NORTHWEST RESEARCH INSTITUTE 2020-10-29 US disclosed
US-10751317-B2 Methods and compositions for increasing the potency of antifungal agents PACIFIC NORTHWEST RESEARCH INSTITUTE (US) 2020-08-25 US disclosed
US-10577383-B2 Macrocyclic inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-03 US disclosed
US-20190177340-A1 MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE BRISTOL MYERS SQUIBB CO (US) 2019-06-13 US disclosed
CN-109689661-A Macrocyclic inhibitors of myeloperoxidase 百时美施贵宝公司 2019-04-26 CN disclosed
US-20170296502-A1 METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS PACIFIC NORTHWEST RESEARCH INSTITUTE 2017-10-19 US disclosed
US-20170296502-A1 METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS PACIFIC NORTHWEST RESEARCH INSTITUTE 2017-10-19 US disclosed
US-9440992-B2 5,7-disubstituted thiazolo[4,5-D]pyrimidines as chemokine inhibitors Acturum Life Science AB (SE) 2016-09-13 US disclosed
WO-2016057563-A1 METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE (US) 2016-04-14 WO disclosed
US-8088780-B2 5,7-disubstituted thiazolo[4,5-D]pyrimidines for the selective inhibition of chemokine receptors ASTRAZENECA AB (SE) 2012-01-03 US disclosed
US-7947693-B2 2R)-2-[(2-amino-5-{[(1S)-1-(2-fluorophenyl)ethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]pentan-1-ol; neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases su COPD, asthma ASTRAZENECA AB (SE) 2011-05-24 US disclosed
US-20110092519-A1 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS ASTRAZENECA AB (SE) 2011-04-21 US disclosed
EP-1869056-B1 NOVEL 5-SUBSTITUTED 7-AMINO-Ý1,3¨THIAZOLOÝ4,5-D¨PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2010-11-10 EP disclosed
US-20090124637-A1 Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 ASTRAZENECA AB (SE) 2009-05-14 US disclosed
US-20080214578-A1 Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 ACTURUM REAL ESTATE AB (SE) 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10751317-B2 Methods and compositions for increasing the potency of antifungal agents ERG28, DPM1, CYP51A1 ENPP2 4379/4885GLA 1219/4885GSK3B 3140/4885
US-20190177340-A1 MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE EPX, MPO, SERPINB1 ENPP2 116/4885GLA 1178/4885GSK3B 3112/4885
US-20200338036-A1 METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS ERG28, DPM1, CYP51A1 ENPP2 4379/4885GLA 1219/4885GSK3B 3140/4885
US-20170296502-A1 METHODS AND COMPOSITIONS FOR INCREASING THE POTENCY OF ANTIFUNGAL AGENTS ERG28, DPM1, CYP51A1 ENPP2 4379/4885GLA 1219/4885GSK3B 3140/4885
US-20110092519-A1 5,7-DISUBSTITUTED THIAZOLO[4,5-D]PYRIMIDINES AS CHEMOKINE INHIBITORS CX3CR1, CCR2, CXCR3 ENPP2 894/4885GLA 4723/4885GSK3B 3298/4885
US-20240174683-A1 MAP4K1 INHIBITORS MAP3K4, MAP4K4, MAP4K1 ENPP2 522/4885GLA 3651/4885GSK3B 386/4885
US-20080214578-A1 Novel 5-Substituted 7-Amino-[1,3]Thiazolo[4,5-D]Pyrimidine Derivatives 793 CX3CR1, CCR2, CXCR3 ENPP2 1161/4885GLA 4473/4885GSK3B 3622/4885
US-10577383-B2 Macrocyclic inhibitors of myeloperoxidase EPX, MPO, SERPINB1 ENPP2 116/4885GLA 1178/4885GSK3B 3112/4885
US-20090124637-A1 Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794 CX3CR1, CCR2, CCR5 ENPP2 1193/4885GLA 4756/4885GSK3B 4294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.